# Arkuda Therapeutics

**Canonical:** https://apis.io/providers/arkuda-therapeutics/  
**APIs profiled:** 0

Arkuda Therapeutics, Inc. was a privately held, preclinical-stage biotechnology company based in Watertown, Massachusetts, founded in 2018 by Gerhard Koenig, Ph.D. and Duane Burnett to develop small-molecule enhancers of lysosomal function for neurodegenerative disease. Its lead biology targeted progranulin (GRN) and lysosomal dysfunction in frontotemporal dementia (FTD-GRN), Alzheimer's disease and Parkinson's disease. Arkuda closed a $44M Series A in November 2019 and a $64M Series B in February 2022, backed by Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission BioCapital and Eli Lilly and Company. On 27 February 2024 it entered an option and asset purchase agreement with Johnson & Johnson, and on 9 January 2025 Johnson & Johnson (through Janssen Pharmaceuticals) exercised that option and acquired the entire portfolio of lysosomal function enhancers. Independent operations concluded thereafter; founder and CEO Gerhard Koenig became CEO of Augustine Therapeutics in January 2025. Arkuda was a therapeutics developer, not a software company: it never operated a developer program, public API, SDK or machine-readable API contract, and both of its former domains have since lapsed.

## Kin Score — 3.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 3.9).

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Drug Discovery, Neurodegenerative Disease, Therapeutics, Acquired

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/arkuda-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.